There are some promising in vitro results showing that inhibitors against prenyl-binding protein PDEδ, which prevents KRAS from localizing to the plasma membrane, inhibit the growth of KRAS mutant tumor cell lines [40,41]. The gene discussed is KRAS; the disease is neoplasm.